A Study of Barrett's Esophagus Patients to Investigate Quality of Life and Fear of Cancer, and Optimize a Risk Model Based on Biomarkers and New Technologies to Better Predict the Development of Cancer
Conditions
Barrett's Esophagus · Esophageal Adenocarcinoma
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
University Hospital Antwerp, Edegem, Antwerpen, Belgium
Contact: Principal Investigator (Prof. Dr. Sheila Krishnadath)Sint-Augustinus Hospital (ZAS), Wilrijk, Antwerpen, Belgium
Contact: Principal Investigator (Dr. Thomas Botelberge)UZ Gent, Ghent, Belgium
Contact: Principal Investigator (Dr. David Tate)AZ Delta, Roeselare, Belgium
Contact: Principal Investigator (Dr. Dominiek De Wulf)Rigshospitalet, Copenhagen, Denmark
Contact: Study coordinator (Prof. Dr. Michael Patrick Achiam) · michael.patrick.achiam.01@regionh.dk · +45 35 45 04 41Contact: Principal Investigator (Prof. Dr. Michael Patrick Achiam)CHU LILLE - Centre Hospitalier Universitaire de Lille, Lille, France
Contact: Principal Investigator (Prof. Dr. Guillaume Piessen)St James's Hospital, Dublin, Ireland
Contact: Principal Investigator (Prof. Jacintha O Sullivan)IRCCS Ospedale San Raffaele, Milan, Milano, Italy
Contact: Principal Investigator (Dr. Silvio Danese)Karolinska University Hospital, Solna, Sweden
Contact: Study coordinator (Dr. Henrik Maltzman)Contact: Principal Investigator (Dr. Fredrik Klevebro)
Study leads
Sheila Krishnadath
Principal Investigator
Universitair Ziekenhuis Antwerpen (UZA)